Update: Genetic polymorphism of drug metabolizing enzymes in humans

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 5, 1999, Pages 323-329

  Tanaka, E ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ALCOHOL DEHYDROGENASE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CODEINE; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DEXTROMETHORPHAN; DIAZEPAM; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG; DRUG METABOLIZING ENZYME; ENZYME VARIANT; HALOPERIDOL; HYDRAZINE; IMIPRAMINE; ISONIAZID; LIVER ENZYME; METHYLTRANSFERASE; METOPROLOL; NEUROLEPTIC AGENT; NICOTINE; OMEPRAZOLE; PERPHENAZINE; PROPRANOLOL; SPARTEINE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CANCER SUSCEPTIBILITY; DRUG DOSE; DRUG INTERACTION; GENETIC POLYMORPHISM; HUMAN; RACE DIFFERENCE;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC;

EID: 0032757179     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00236.x     Document Type: Article

References (51)

1. 1. Clark DW. (1985) Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs, 29, 342-375.
2. 2. Nakamura K, Goto F, Ray WA, et al. (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clinical Pharmacology and Therapeutics, 38, 402-408.
3. 3. Gibson GC, Skett P. (1996) Factors affecting drug metabolism: internal factors. In: Gibson GG, Skett P, eds. Introduction to Drug Metabolism, 2nd edn. London: Chapman & Hall, 107-156.
4. 4. Vesell ES, Page JG. (1968) Genetic control of drug levels in man: antipyrine. Science, 161, 72-73.
5. 5. Odani A, Hashimoto Y, Otsuki Y, et al. (1997) Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clinical Pharmacology and Therapeutics, 62, 287-292.
6. 6. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T. (1997) Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics, 7, 103-113.
7. 7. Mamiya K, Ieiri I, Shimamoto J, et al. (1998) The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia, 39, 1317-1323.
8. 8. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Molecular Pharmacology, 46, 594-598.
9. 9. Xiao ZS, Goldstein JA, Xie HG, et al. (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. Journal of Pharmacology and Experimental Therapeutics, 281, 604-609.
10. 10. Ferguson RJ, De Morais SM, Benhamou S, et al. (1998) A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. Journal of Pharmacology and Experimental Therapeutics, 284, 356-361.
11. 11. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T. (1997) Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics, 7, 103-113.
12. 12. Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. (1990) Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clinical Pharmacology and Therapeutics, 47, 79-85.
13. 13. Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. (1992) Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics, 2, 25-31.
14. 14. Bertilsson L. (1995) Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clinical Pharmacokinetics, 29, 192-209.
15. 15. Engel G, Hofmann U, Kroemer HK. (1996) Prediction of CYP2D6-mediated polymorphic drug metabolism (sparteine type) based on in vitro investigations. Journal of Chromatography B: Biomedical Applications, 678, 93-103.
16. 16. Bertilsson L, Dahl ML, Sjoqvist F, et al. (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet, 341(8836), 63.
17. 17. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proceedings of the National Academy of Sciences of the United States of America, 90, 11825-11829.
18. 18. Daly AK, Brockmoller J, Broly F, et al. (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics, 6, 193-201.
19. 19. McCarver DG, Byun R, Hines RN, Hichme M, Wegenek WA. (1998) A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicology Applied Pharmacology, 152, 276-281.
20. 20. Weber WW. (1997) Pharmacogenetics, Applications of Pharmacogenitics Concepts. New York: Oxford University Press, 189-201.
21. 21. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. (1991) Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proceedings of the National Academy of Sciences of the Untied States of America, 88, 5237-5241.
22. 22. Hickman D, Sim E. (1991) N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochemical Pharmacology, 42, 1007-1014.
23. 23. Rothman N, Hayes RB, Bi W, et al. (1993) Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics, 3, 250-255.
24. 24. Evans DA. (1989) N-acetyltransferase. Pharmacology and Therapeutics, 42, 157-234.
25. 25. Grant DM. (1993) Molecular genetics of the N-acetyltransferases. Pharmacogenetics, 3, 45-50.
26. 26. Weber WW, Vatsis KP. (1993) Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics, 3, 209-212.
27. 27. Milano G, Etienne MC. (1994) Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics, 4, 301-306.
28. 28. Weinshilboum RM, Sladek SL. (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. American Journal of Human Genetics, 32, 651-662.
29. 29. Woodson LC, Dunnette JH, Weinshilboum RM. (1982) Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. Journal of Pharmacology and Experimental Therapeutics, 222, 174-181.
30. 30. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. Journal of Clinical Investigation, 98, 610-615.
31. 31. Yoshida A. (1992) Molecular genetics of human aldehyde dehydrogenase. Pharmacogenetics, 2, 139-147.
32. 32. Ward RJ, McPherson AJ, Chow C, et al. (1994) Identification and characterisation of alcohol-induced flushing in Caucasian subjects. Alcohol and Alcoholism, 29, 433-438.
33. 33. Hodgkin WE, Giblett ER, Levine H, Bauer W, Motulsky AG. (1965) Complete pseudocholinesterase deficiency: genetic and immunologic characterization. Journal of Clinical Investigation, 44, 486-493.
34. 34. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics, 4, 39-42.
35. 35. Miners JO, Birkett DJ. (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. British Journal of Clinical Pharmacology, 45, 525-538.
36. 36. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. Journal of Biological Chemistry, 269, 15419-15422.
37. 37. Gonzalez FJ, Meyer UA. (1991) Molecular genetics of the debrisoquin-sparteine polymorphism. Clinical Pharmacology and Therapeutics, 50, 233-238.
38. 38. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA and Cell Biology, 10, 545-558.
39. 39. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR. (1991) Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics, 1, 33-41.
40. 40. Evans WE, Relling MV. (1991) Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Pharmacogenetics, 1, 143-148.
41. 41. Tyndale R, Aoyama T, Broly F, et al. (1991) Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics, 1, 26-32.
42. 42. Yokota H, Tamura S, Furuya H, et al. (1993) Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics, 3, 256-263.
43. 43. Steen VM, Molven A, Aarskog NK, Gulbrandsen AK. (1995) Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. Human Molecular Genetics, 4, 2251-2257.
44. 44. Akullu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. Journal of Pharmacology and Experimental Therapeutics, 278, 441-446.
45. 45. Meyer UA, Zanger UM. (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annual Review of Pharmacology and Toxicology, 37, 269-296.
46. 46. Degtyarenko KN, Fabian P. (1996) The directory of P450-containing systems on World Wide Web. Computer Applications in the Biosciences, 12, 237-240.
47. 47. Okumura K, Kita T, Chikazawa S, Komada F, Iwakawa S, Tanigawara Y. (1997) Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clinical Pharmacology and Therapeutics, 61, 509-517.
48. 48. Goldstein JA, Blaisdell J. (1996) Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods in Enzymology, 272, 210-218.
49. 49. Nelson DR, Koymans L, Kamataki T, et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Phrmacogenetics, 6, 1-42.
50. 50. Smith G, Stubbins MJ, Harries LW, Wolf CR. (1998) Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica, 28, 1129-1165.
51. 51. Ronald RT, Urichuk LJ. (1999) Polymorphic cytochrome P450 and drugs used in psychiatry. Cellular and Molecular Neurobiology, 19, 325-353.